Dion J. Weisler
Dion J. Weisler's purchase track record
Dion J. Weisler has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/25/2021 | INTC | $998K | +5.9% | -3.4% | -5.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Intel Shares Drop 3% Amid AI Chip Rotation. Intel shares fell 3% along with AMD as investors rotate out of AI‑focused chip names. The drop comes amid a broader selloff in the sector after concerns about an AI bubble. Analysts are watching Intel’s upcoming earnings to see if it can meet expectations.
Transaction History
| TMO | ▼ Sell | Tax Withholding | 80 | $36K | 5/20/2026 | View on chart |
| TMO | ▲ Buy | Grant | 499 | $0 | 5/20/2026 | View on chart |
| INTC | ▲ Buy | Option Exercise | 12,552 | — | 5/7/2026 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 54 | $21K | 5/21/2025 | View on chart |
| TMO | ▲ Buy | Grant | 565 | $0 | 5/21/2025 | View on chart |
| INTC | ▼ Sell | Tax Withholding | 1,189 | $24K | 5/6/2025 | View on chart |
| INTC | ▲ Buy | Option Exercise | 7,403 | — | 5/6/2025 | View on chart |
| INTC | ▼ Sell | Tax Withholding | 2,221 | $44K | 5/6/2025 | View on chart |
| INTC | ▲ Buy | Option Exercise | 3,961 | — | 5/6/2025 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 59 | $35K | 5/22/2024 | View on chart |
| TMO | ▲ Buy | Grant | 339 | $0 | 5/22/2024 | View on chart |
| INTC | ▲ Buy | Option Exercise | 138 | — | 5/7/2024 | View on chart |
| INTC | ▼ Sell | Tax Withholding | 42 | $1K | 5/7/2024 | View on chart |
| INTC | ▲ Buy | Option Exercise | 7,152 | — | 5/7/2024 | View on chart |
| INTC | ▼ Sell | Tax Withholding | 2,146 | $67K | 5/7/2024 | View on chart |
| INTC | ▲ Buy | Option Exercise | 3,129 | — | 5/7/2024 | View on chart |
| INTC | ▼ Sell | Tax Withholding | 939 | $29K | 5/7/2024 | View on chart |
| INTC | ▲ Buy | Option Exercise | 3,982 | — | 1/30/2024 | View on chart |
| INTC | ▼ Sell | Tax Withholding | 1,195 | $52K | 1/30/2024 | View on chart |
| TMO | ▲ Buy | Grant | 392 | $0 | 5/24/2023 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 53 | $28K | 5/18/2023 | View on chart |
| INTC | ▼ Sell | Tax Withholding | 1,449 | $42K | 5/11/2023 | View on chart |
| INTC | ▲ Buy | Option Exercise | 4,828 | — | 5/11/2023 | View on chart |
| INTC | ▲ Buy | Option Exercise | 2,152 | — | 1/31/2023 | View on chart |
| INTC | ▼ Sell | Tax Withholding | 646 | $18K | 1/31/2023 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 33 | $18K | 5/18/2022 | View on chart |
| TMO | ▲ Buy | Grant | 369 | $0 | 5/18/2022 | View on chart |
| INTC | ▲ Buy | Option Exercise | 3,720 | — | 5/12/2022 | View on chart |
| INTC | ▼ Sell | Tax Withholding | 1,116 | $47K | 5/12/2022 | View on chart |
| INTC | ▲ Buy | Option Exercise | 453 | — | 1/30/2022 | View on chart |
| INTC | ▼ Sell | Tax Withholding | 136 | $7K | 1/30/2022 | View on chart |
| INTC | ▲ Buy | Open Market | 5,149 | $248K | 10/28/2021 | View on chart |
| INTC | ▲ Buy | Open Market | 5,202 | $250K | 10/28/2021 | View on chart |
| INTC | ▲ Buy | Open Market | 2,064 | $100K | 10/26/2021 | View on chart |
| INTC | ▲ Buy | Open Market | 1,040 | $50K | 10/26/2021 | View on chart |
| INTC | ▲ Buy | Open Market | 2,043 | $100K | 10/26/2021 | View on chart |
| INTC | ▲ Buy | Open Market | 5,015 | $250K | 10/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Thermo Fisher Outperforms on Life Sciences Recovery
Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.
Thermo Fisher Outperforms on Life Sciences Recovery. Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.